There is currently no cure for coronavirus, however, that hasn’t stopped companies from preying on consumers’ fears, as a new raft of FDA warning letters makes clear.
The sad news came this week of the death of a young girl who started a movement, one which has exposed again the built-in strains of how the dietary supplement market is regulated in the United States.
The US Food and Drug Administration has issued an additional six warning letters in recent days on coronavirus claims. The letters coincide with an industry coalition raising a red flag on the growing flood of such claims on dietary supplement-type products.
A coalition of dietary supplement industry trade associations have come out in support of FDA actions against fraudulent coronavirus treatment claims and have urged retailers to not stock products with such claims on their labels.
A wide ranging recall of products made by a New York-based contract manufacturer holds lessons supplement firms can use to avoid similar problems in the future, experts say.
The US Food and Drug Administration has issued another warning letter on COVID-19 claims. This one was issued to a Nevada company marketing CBD products.
Industry experts have slammed statements made in a recent JAMA Viewpoint that called for probiotics to be regulated to the same standard as drugs, and decried the “paucity of high-quality data supporting the value of probiotics”.
If only social distancing could stop the spread of misinformation. A prominent natural products chemist shares four steps on differentiating the real from the fake.
The National Advertising Division has directed Church & Dwight to stop making a claim of better absorption on its line of gummy vitamins. The company has responded by appealing the decision to a review board.
The $2 trillion stimulus packaged passed unanimously by the US Senate this morning will have important implications for the dietary supplement industry that may help companies survive the worst of the coronavirus crisis impacts.
Dietary supplement companies may store adverse event reports and submit them after the present crisis is past, the US Food and Drug Administration said recently.
Synthetic astaxanthin product developer Cardax has released a white paper and reportedly filed a patent application on the ingredient’s antiviral properties and in publicizing the fact has treaded on the disease claim line according to legal experts.
In light of the ongoing novel Coronavirus (COVID19) public health emergency, IPA World Congress + Probiota Americas has been postponed until November 16-18, 2020 at the Crystal Gateway Marriott Hotel, Washington DC.
